Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Health Ministry to Introduce New System for Online Import and Export Declarations as Early as Next Autumn
September 9, 2013
- Council on Regulatory Reform’s Working Group to Present Recommendations by Year-End for More Effective Use of (Pre-Trial) Clinical Study Data for Earlier Marketing Approval
September 9, 2013
- MHLW Sets to Tap into Advanced Healthcare Scheme to Shed Drug Lag for Anticancer Agents
September 5, 2013
- CSIMC’s Cost-Effective Assessment Subcommittee Fails to Forge Consensus; Draft Interim Report Simply Lists Pros and Cons
September 5, 2013
- MHLW’s FY2014 Budget Request Earmarks Funds to Expand Generic Drug Savings Notification Project to All Insurers
September 5, 2013
- Key Govt Council Sets Up 4 Subcommittees; Scraping of Insurance Coverage for OTC-Like Drugs Up for Discussion
September 4, 2013
- PAFSC Second Committee on Drugs to Discuss Hepatitis C Treatment Simeprevir at Meeting on September 13
September 3, 2013
- Diovan Panel Heats Up Over Future Course of Discussions; “Find Out Truth” vs “Identify Structural Flaws”
September 3, 2013
- MHLW Aims to Reduce Medical Expenditure by 1 Trillion Yen by FY2025 through Measures to Promote Generic Drug Use
September 2, 2013
- MHLW Adds Interstitial Pneumonia as Serious Adverse Reaction of Simponi
August 30, 2013
- 8% Sales Tax Will Be Tacked on Drug Market Prices, How It Will Be Shown Not Yet Agreed: MHLW Panel
August 30, 2013
- CSIMC’s DPC Subcommittee to Reconsider Use of Functional Evaluation Coefficient II to Evaluate Rate of Generic Drug Use
August 30, 2013
- MHLW’s Health Bureau to Seek 408.9 Billion Yen for 2014 Budget, 21.1 Billion for Infectious Disease Prevention
August 29, 2013
- HPB’s FY2014 Budget Request Earmarks Funds to Strength System of Hospitals that Accept All Emergency Patients
August 29, 2013
- University Hospitals Asked to Inspect Own Clinical Trials amid Diovan Jitters
August 28, 2013
- MHLW Budget Requests Feature 114.1 Billion Yen for Japan NIH, Drug Discovery Network
August 28, 2013
- MHLW’s Economic Affairs Division Honing in on “4th Round” of Distribution Reform; Era of Bundling Won’t Return
August 27, 2013
- Second Committee Recommends Approval for Japan’s First LABA/LAMA Combination Drug
August 27, 2013
- PMDA Provides Risk Information on 10 Ethical Drugs Currently Under Evaluation
August 27, 2013
- New Ethical Guidelines to Include Preventive Measures against Misconduct in Research: Health, Education Ministries’ Interim Report
August 26, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…